The combination of metyrapone and oxazepam for the treatment of cocaine and other drug addictions

Advances in Pharmacology

Volumn 69, Issue , 2014, Pages 419-479

  Goeders, Nicholas E ^a   Guerin, Glenn F ^a   Schmoutz, Christopher D ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Addiction; Cocaine; Corticosterone; Metyrapone; Neurosteroids; Oxazepam; Self administration; Stress

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; COCAINE; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; KETOCONAZOLE; METHAMPHETAMINE; METYRAPONE; MUSCIMOL; NEUROSTEROID; NICOTINE; OXAZEPAM; ANXIOLYTIC AGENT;

ADRENALECTOMY; ANXIETY; ARTICLE; BENZODIAZEPINE DEPENDENCE; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; CORTICOSTERONE BLOOD LEVEL; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG SCREENING; DRUG SELF ADMINISTRATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; METHAMPHETAMINE DEPENDENCE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RELAPSE; STRESS; TOBACCO DEPENDENCE; ADDICTION; ANIMAL; MENTAL STRESS; NEUROSTEROIDS; PSYCHOLOGICAL ASPECT; REVIEW; SELF-ADMINISTRATION; TREATMENT OUTCOME;

ADDICTION; COCAINE; CORTICOSTERONE; METYRAPONE; NEUROSTEROIDS; OXAZEPAM; SELF-ADMINISTRATION; STRESS;

ANIMALS; ANTI-ANXIETY AGENTS; COCAINE-RELATED DISORDERS; HUMANS; METYRAPONE; OXAZEPAM; STRESS, PSYCHOLOGICAL; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84893199472     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420118-7.00011-1     Document Type: Chapter

References (277)

1. Agis-Balboa R.C., Pinna G., Zhubi A., Maloku E., Veldic M., Costa E., et al. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(39):14602-14607.
2. Amrein R., Leishman B., Bentzinger C., Roncari G. Flumazenil in benzodiazepine antagonism. Actions and clinical use in intoxications and anaesthesiology. Medical Toxicology and Adverse Drug Experience 1987, 2(6):411-429.
3. Anker J.J., Carroll M.E. Reinstatement of cocaine seeking induced by drugs, cues, and stress in adolescent and adult rats. Psychopharmacology 2010, 208(2):211-222.
4. Anker J.J., Carroll M.E. Sex differences in the effects of allopregnanolone on yohimbine-induced reinstatement of cocaine seeking in rats. Drug and Alcohol Dependence 2010, 107(2-3):264-267.
5. Anker J.J., Holtz N.A., Zlebnik N., Carroll M.E. Effects of allopregnanolone on the reinstatement of cocaine-seeking behavior in male and female rats. Psychopharmacology 2009, 203(1):63-72.
6. Anker J.J., Zlebnik N.E., Carroll M.E. Differential effects of allopregnanolone on the escalation of cocaine self-administration and sucrose intake in female rats. Psychopharmacology 2010, 212(3):419-429.
7. Anthony J.C., Tien A.Y., Petronis K.R. Epidemiologic evidence on cocaine use and panic attacks. American Journal of Epidemiology 1989, 129(3):543-549.
8. Aronson T.A., Craig T.J. Cocaine precipitation of panic disorder. The American Journal of Psychiatry 1986, 143(5):643-645.
9. Baldessarini R.J. Drugs and the treatment of psychiatric disorders: Psychosis and anxiety. Goodman & Gilman's the pharmacological basis of therapeutics 1996, 399-430. McGraw-Hill, New York, NY. 9th ed. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Gilman (Eds.).
10. Barbaccia M.L., Serra M., Purdy R.H., Biggio G. Stress and neuroactive steroids. International Review of Neurobiology 2001, 46:243-272.
11. Barrett A.C., Negus S.S., Mello N.K., Caine S.B. Effect of GABA agonists and GABA-A receptor modulators on cocaine- and food-maintained responding and cocaine discrimination in rats. The Journal of Pharmacology and Experimental Therapeutics 2005, 315(2):858-871.
12. Barros H.M., Miczek K.A. Withdrawal from oral cocaine in rate: Ultrasonic vocalizations and tactile startle. Psychopharmacology 1996, 125(4):379-384.
13. Baulieu E.E. Neurosteroids: A new function in the brain. Biology of the Cell 1991, 71(1-2):3-10.
14. Baulieu E.E. Neurosteroids: Of the nervous system, by the nervous system, for the nervous system. Recent Progress in Hormone Research 1997, 52:1-32.
15. Baulieu E.E., Robel P. Neurosteroids: A new brain function?. The Journal of Steroid Biochemistry and Molecular Biology 1990, 37(3):395-403.
16. Baumann M.H., Gendron T.M., Becketts K.M., Henningfield J.E., Gorelick D.A., Rothman R.B. Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Biological Psychiatry 1995, 38(11):751-755.
17. Belelli D., Lambert J.J. Neurosteroids: Endogenous regulators of the GABA(A) receptor. Nature Reviews. Neuroscience 2005, 6(7):565-575.
18. Bergman S.A. The benzodiazepine receptor. Anesthesia Progress 1986, 33(5):213-219.
19. Bonson K.R., Grant S.J., Contoreggi C.S., Links J.M., Metcalfe J., Weyl H.L., et al. Neural systems and cue-induced cocaine craving. Neuropsychopharmacology 2002, 26(3):376-386.
20. Brady K.T., Lydiard R.B. Bipolar affective disorder and substance abuse. Journal of Clinical Psychopharmacology 1992, 12(1 Suppl.):17S-22S.
21. Brozic P., Smuc T., Gobec S., Rizner T.L. Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1. Molecular and Cellular Endocrinology 2006, 259(1-2):30-42.
22. Buffalari D.M., Feltenstein M.W., See R.E. The effects of varied extinction procedures on contingent cue-induced reinstatement in Sprague-Dawley rats. Psychopharmacology 2013, 230(2):319-327.
23. Calogero A.E., Gallucci W.T., Kling M.A., Chrousos G.P., Gold P.W. Cocaine stimulates rat hypothalamic corticotropin-releasing hormone secretion in vitro. Brain Research 1989, 505(1):7-11.
24. Chebib M., Johnston G.A. The 'ABC' of GABA receptors: A brief review. Clinical and Experimental Pharmacology & Physiology 1999, 26(11):937-940.
25. Chesley S.F., Schatzki A.D., DeUrrutia J., Greenblatt D.J., Shader R.I., Miller L.G. Cocaine augments peripheral benzodiazepine binding in humans. The Journal of Clinical Psychiatry 1990, 51(10):404-406.
26. Childress A.R., Mozley P.D., McElgin W., Fitzgerald J., Reivich M., O'Brien C.P. Limbic activation during cue-induced cocaine craving. The American Journal of Psychiatry 1999, 156(1):11-18.
27. Chouinard G. Issues in the clinical use of benzodiazepines: Potency, withdrawal, and rebound. The Journal of Clinical Psychiatry 2004, 65(Suppl. 5):7-12.
28. Costall B., Kelly M.E., Naylor R.J., Onaivi E.S. The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacology, Biochemistry, and Behavior 1989, 33(1):197-203.
29. Czlonkowska A.I., Zienowicz M., Bidzinski A., Maciejak P., Lehner M., Taracha E., et al. The role of neurosteroids in the anxiolytic, antidepressive- and anticonvulsive effects of selective serotonin reuptake inhibitors. Medical Science Monitor 2003, 9(11):RA270-RA275.
30. Darbra S., Pallares M. Alterations in neonatal neurosteroids affect exploration during adolescence and prepulse inhibition in adulthood. Psychoneuroendocrinology 2010, 35(4):525-535.
31. Deminiere J.M., Piazza P.V., Guegan G., Abrous N., Maccari S., Le Moal M., et al. Increased locomotor response to novelty and propensity to intravenous amphetamine self-administration in adult offspring of stressed mothers. Brain Research 1992, 586(1):135-139.
32. De Souza E.B., Goeders N.E., Kuhar M.J. Benzodiazepine receptors in rat brain are altered by adrenalectomy. Brain Research 1986, 381(1):176-181.
33. DeVries A.C., Pert A. Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor. Psychopharmacology 1998, 137(4):333-340.
34. de Wit H., Stewart J. Drug reinstatement of heroin-reinforced responding in the rat. Psychopharmacology 1983, 79(1):29-31.
35. Dhir A., Rogawski M.A. Role of neurosteroids in the anticonvulsant activity of midazolam. British Journal of Pharmacology 2012, 165(8):2684-2691.
36. Doron R., Fridman L., Gispan-Herman I., Maayan R., Weizman A., Yadid G. DHEA, a neurosteroid, decreases cocaine self-administration and reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology 2006, 31(10):2231-2236.
37. Dubrovsky B.O. Steroids, neuroactive steroids and neurosteroids in psychopathology. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005, 29(2):169-192.
38. Dworkin S.I., D'Costa A., Goeders N.E., Hoffman E. A progressive-ratio schedule for cocaine administration: Effects of cocaine dose and diazepam. Neuroscience Abstracts 1989, 15:802.
39. Dworkin S.I., Mirkis S., Smith J.E. Response-dependent versus response-independent presentation of cocaine: Differences in the lethal effects of the drug. Psychopharmacology 1995, 117(3):262-266.
40. Edwards C.R., Benediktsson R., Lindsay R.S., Seckl J.R. 11 beta-Hydroxysteroid dehydrogenases: Key enzymes in determining tissue-specific glucocorticoid effects. Steroids 1996, 61(4):263-269.
41. Engelhardt D., Dorr G., Jaspers C., Knorr D. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klinische Wochenschrift 1985, 63(13):607-612.
42. Erb S. Evaluation of the relationship between anxiety during withdrawal and stress-induced reinstatement of cocaine seeking. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34(5):798-807.
43. Erb S., Shaham Y., Stewart J. Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug-free period. Psychopharmacology 1996, 128(4):408-412.
44. Erb S., Shaham Y., Stewart J. The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. The Journal of Neuroscience 1998, 18(14):5529-5536.
45. Ettenberg A., Geist T.D. Animal model for investigating the anxiogenic effects of self-administered cocaine. Psychopharmacology 1991, 103(4):455-461.
46. Extein I.L., Gold M.S. Hypothesized neurochemical models for psychiatric syndromes in alcohol and drug dependence. Journal of Addictive Diseases 1993, 12(3):29-43.
47. Farnsworth M.G. Benzodiazepine abuse and dependence: Misconceptions and facts. The Journal of Family Practice 1990, 31(4):393-400.
48. Ferster C.B. Schedules of reinforcement with Skinner. 1970. Journal of the Experimental Analysis of Behavior 2002, 77(3):303-311.
49. File S.E., Pellow S. Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788. Psychopharmacology 1986, 88(1):1-11.
50. Fontana D.J., Commissaris R.L. Effects of cocaine on conflict behavior in the rat. Life Sciences 1989, 45(9):819-827.
51. Forman L.J., Estilow S. Cocaine influences beta-endorphin levels and release. Life Sciences 1988, 43(4):309-315.
52. Fumagalli F., Moro F., Caffino L., Orru A., Cassina C., Giannotti G., et al. Region-specific effects on BDNF expression after contingent or non-contingent cocaine i.v. self-administration in rats. The International Journal of Neuropsychopharmacology 2013, 16(4):913-918.
53. Garavan H., Pankiewicz J., Bloom A., Cho J.K., Sperry L., Ross T.J., et al. Cue-induced cocaine craving: Neuroanatomical specificity for drug users and drug stimuli. The American Journal of Psychiatry 2000, 157(11):1789-1798.
54. Gawin F.H. New uses of antidepressants in cocaine abuse. Psychosomatics 1986, 27(11 Suppl.):24-29.
55. Gawin F.H., Ellinwood E.H. Cocaine and other stimulants. Actions, abuse, and treatment. The New England Journal of Medicine 1988, 318(18):1173-1182.
56. Gawin F.H., Ellinwood E.H. Cocaine dependence. Annual Review of Medicine 1989, 40:149-161.
57. Gay G.R. You've come a long way, baby! Coke time for the new American lady of the eighties. Journal of Psychoactive Drugs 1981, 13(4):297-318.
58. Gay G.R. Clinical management of acute and chronic cocaine poisoning. Annals of Emergency Medicine 1982, 11(10):562-572.
59. Ghadirian A.M., Engelsmann F., Dhar V., Filipini D., Keller R., Chouinard G., et al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biological Psychiatry 1995, 37(6):369-375.
60. Goeders N.E. Cocaine differentially affects benzodiazepine receptors in discrete regions of the rat brain: Persistence and potential mechanisms mediating these effects. The Journal of Pharmacology and Experimental Therapeutics 1991, 259(2):574-581.
61. Goeders N.E. A neuroendocrine role in cocaine reinforcement. Psychoneuroendocrinology 1997, 22(4):237-259.
62. Goeders N.E. The HPA axis and cocaine reinforcement. Psychoneuroendocrinology 2002, 27(1-2):13-33.
63. Goeders N.E. Stress and cocaine addiction. The Journal of Pharmacology and Experimental Therapeutics 2002, 301(3):785-789.
64. Goeders N.E. Stress, motivation, and drug addiction. Current Directions in Psychological Science 2004, 13(1):33-35.
65. Goeders N., Bell V., Guidroz A., McNulty M. Dopaminergic involvement in the cocaine-induced up-regulation of benzodiazepine receptors in the rat caudate nucleus. Brain Research 1990, 515(1-2):1-8.
66. Goeders N.E., Bienvenu O.J., De Souza E.B. Chronic cocaine administration alters corticotropin-releasing factor receptors in the rat brain. Brain Research 1990, 531(1-2):322-328.
67. Goeders N.E., Clampitt D.M. Potential role for the hypothalamo-pituitary-adrenal axis in the conditioned reinforcer-induced reinstatement of extinguished cocaine seeking in rats. Psychopharmacology 2002, 161(3):222-232.
68. Goeders N.E., Clampitt D.M., Keller C., Sharma M., Guerin G.F. Alprazolam and oxazepam block the cue-induced reinstatement of extinguished cocaine seeking in rats. Psychopharmacology 2009, 201(4):581-588.
69. Goeders N.E., Cohen A., Fox B.S., Azar M.R., George O., Koob G.F. Effects of the combination of metyrapone and oxazepam on intravenous nicotine self-administration in rats. Psychopharmacology 2012, 223(1):17-25.
70. Goeders N.E., De Souza E.B., Kuhar M.J. Benzodiazepine receptor GABA ratios: Regional differences in rat brain and modulation by adrenalectomy. European Journal of Pharmacology 1986, 129(3):363-366.
71. Goeders J.E., Goeders N.E. Effects of oxazepam on methamphetamine-induced conditioned place preference. Pharmacology, Biochemistry, and Behavior 2004, 78(1):185-188.
72. Goeders N.E., Guerin G.F. Non-contingent electric footshock facilitates the acquisition of intravenous cocaine self-administration in rats. Psychopharmacology 1994, 114(1):63-70.
73. Goeders N.E., Guerin G.F. Effects of surgical and pharmacological adrenalectomy on the initiation and maintenance of intravenous cocaine self-administration in rats. Brain Research 1996, 722(1-2):145-152.
74. Goeders N.E., Guerin G.F. Role of corticosterone in intravenous cocaine self-administration in rats. Neuroendocrinology 1996, 64(5):337-348.
75. Goeders N.E., Guerin G.F. Effects of ketoconazole on intravenous cocaine self-administration in rats. NIDA Research Monograph 174, Problems of Drug Dependence, 1996 1997, 180. NIH publication number 97-4236. L.S. Harris (Ed.).
76. Goeders N.E., Guerin G.F. Pretreatment with corticosterone or dexamethasone fails to affect ongoing cocaine self-administration in rats. Neuroscience Abstracts 1999, 25:1872.
77. Goeders N.E., Guerin G.F. Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology 2000, 23(5):577-586.
78. Goeders N.E., Guerin G.F. Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacology, Biochemistry, and Behavior 2008, 91(1):181-189.
79. Goeders N.E., Irby B.D., Shuster C.C., Guerin G.F. Tolerance and sensitization to the behavioral effects of cocaine in rats: Relationship to benzodiazepine receptors. Pharmacology, Biochemistry, and Behavior 1997, 57(1-2):43-56.
80. Goeders N.E., McNulty M.A., Guerin G.F. Effects of alprazolam on intravenous cocaine self-administration in rats. Pharmacology, Biochemistry, and Behavior 1993, 44(2):471-474.
81. Goeders N.E., McNulty M.A., Mirkis S., McAllister K.H. Chlordiazepoxide alters intravenous cocaine self-administration in rats. Pharmacology, Biochemistry, and Behavior 1989, 33(4):859-866.
82. Goeders N.E., Peltier R.L., Guerin G.F. Ketoconazole reduces low dose cocaine self-administration in rats. Drug and Alcohol Dependence 1998, 53(1):67-77.
83. Goeders N.E., Smith J.E. Cortical dopaminergic involvement in cocaine reinforcement. Science 1983, 221(4612):773-775.
84. Goeders N.E., Smith J.E. Intracranial cocaine self-administration into the medial prefrontal cortex increases dopamine turnover in the nucleus accumbens. The Journal of Pharmacology and Experimental Therapeutics 1993, 265(2):592-600.
85. Gomez-Sanchez C.E., Zhou M.Y., Cozza E.N., Morita H., Eddleman F.C., Gomez-Sanchez E.P. Corticosteroid synthesis in the central nervous system. Endocrine Research 1996, 22(4):463-470.
86. Gomez-Sanchez C.E., Zhou M.Y., Cozza E.N., Morita H., Foecking M.F., Gomez-Sanchez E.P. Aldosterone biosynthesis in the rat brain. Endocrinology 1997, 138(8):3369-3373.
87. Gorin R.E., Crabbe J.C., Tanchuck M.A., Long S.L., Finn D.A. Effects of finasteride on chronic and acute ethanol withdrawal severity in the WSP and WSR selected lines. Alcoholism, Clinical and Experimental Research 2005, 29(6):939-948.
88. Grant S., London E.D., Newlin D.B., Villemagne V.L., Liu X., Contoreggi C., et al. Activation of memory circuits during cue-elicited cocaine craving. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(21):12040-12045.
89. Griffiths R.R., Johnson M.W. Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. The Journal of Clinical Psychiatry 2005, 66(Suppl. 9):31-41.
90. Griffiths R.R., McLeod D.R., Bigelow G.E., Liebson I.A., Roache J.D. Relative abuse liability of diazepam and oxazepam: Behavioral and subjective dose effects. Psychopharmacology 1984, 84(2):147-154.
91. Griffiths R.R., Weerts E.M. Benzodiazepine self-administration in humans and laboratory animals-Implications for problems of long-term use and abuse. Psychopharmacology 1997, 134(1):1-37.
92. Griffiths R.R., Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. Journal of Clinical Psychopharmacology 1990, 10(4):237-243.
93. Groh B., Muller W.E. A comparison of the relative in vitro and in vivo binding affinities of various benzodiazepines and related compounds for the benzodiazepine receptor and for the peripheral benzodiazepine binding site. Research Communications in Chemical Pathology and Pharmacology 1985, 49(3):463-466.
94. Gurkovskaya O., Goeders N.E. Effects of CP-154,526 on responding during extinction from cocaine self-administration in rats. European Journal of Pharmacology 2001, 432(1):53-56.
95. Guzman D., Moscarello J.M., Ettenberg A. The effects of medial prefrontal cortex infusions of cocaine in a runway model of drug self-administration: Evidence of reinforcing but not anxiogenic actions. European Journal of Pharmacology 2009, 605(1-3):117-122.
96. Haleem D.J., Kennett G., Curzon G. Adaptation of female rats to stress: Shift to male pattern by inhibition of corticosterone synthesis. Brain Research 1988, 458(2):339-347.
97. Haney M., Maccari S., Le Moal M., Simon H., Piazza P.V. Social stress increases the acquisition of cocaine self-administration in male and female rats. Brain Research 1995, 698(1-2):46-52.
98. Haynes R.C. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. The pharmacological basis of therapeutics 1990, 1431-1462. Pergamon Press, New York, NY. A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.).
99. Hays J.T., Ebbert J.O. Varenicline for tobacco dependence. The New England Journal of Medicine 2008, 359(19):2018-2024.
100. Hays J.T., Ebbert J.O., Sood A. Efficacy and safety of varenicline for smoking cessation. The American Journal of Medicine 2008, 121(4 Suppl. 1):S32-S42.
101. Heesch C.M., Negus B.H., Keffer J.H., Snyder R.W., Risser R.C., Eichhorn E.J. Effects of cocaine on cortisol secretion in humans. The American Journal of the Medical Sciences 1995, 310(2):61-64.
102. Higaki Y., Usami N., Shintani S., Ishikura S., El-Kabbani O., Hara A. Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chemico-Biological Interactions 2003, 143-144:503-513.
103. Hirani K., Sharma A.N., Jain N.S., Ugale R.R., Chopde C.T. Evaluation of GABAergic neuroactive steroid 3alpha-hydroxy-5alpha-pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats. Psychopharmacology 2005, 180(2):267-278.
104. Hirschfeld R.M. Future directions in the treatment of anxiety. Journal of Psychiatric Research 1990, 24(Suppl. 2):163-167.
105. Holmes M.C., Yau J.L., Kotelevtsev Y., Mullins J.J., Seckl J.R. 11 Beta-hydroxysteroid dehydrogenases in the brain: Two enzymes two roles. Annals of the New York Academy of Sciences 2003, 1007:357-366.
106. Hyman S.M., Fox H., Hong K.I., Doebrick C., Sinha R. Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. Experimental and Clinical Psychopharmacology 2007, 15(2):134-143.
107. Iguchi M.Y., Handelsman L., Bickel W.K., Griffiths R.R. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug and Alcohol Dependence 1993, 32(3):257-266.
108. Jain M.R., Khan F.A., Krishna N.S., Subhedar N. Intracranial metyrapone stimulates CRF-ACTH axis in the teleost, Clarias batrachus: Possible role of neurosteroids. Neuroreport 1994, 5(16):2093-2096.
109. Javaid J.I., Notorangelo M.P., Pandey S.C., Reddy P.L., Pandey G.N., Davis J.M. Peripheral benzodiazepine receptors are decreased during cocaine withdrawal in humans. Biological Psychiatry 1994, 36(1):44-50.
110. Joels M., de Kloet E.R. Mineralocorticoid and glucocorticoid receptors in the brain. Implications for ion permeability and transmitter systems. Progress in Neurobiology 1994, 43(1):1-36.
111. Johnston G.A. GABAA agonists as targets for drug development. Clinical and Experimental Pharmacology & Physiology 1992, 19(1):73-78.
112. Joo H.K., Oh S.C., Cho E.J., Park K.S., Lee J.Y., Lee E.J., et al. Midazolam inhibits tumor necrosis factor-alpha-induced endothelial activation: Involvement of the peripheral benzodiazepine receptor. Anesthesiology 2009, 110(1):106-112.
113. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 2006, 296(1):56-63.
114. Kablinger A.S., Lindner M.A., Casso S., Hefti F., DeMuth G., Fox B.S., et al. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: A double-blind, randomized, placebo-controlled pilot study. Journal of Psychopharmacology 2012, 26(7):973-981.
115. Kaminski R.M., Rogawski M.A. 11beta-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis. Neuropharmacology 2011, 61(1-2):133-137.
116. Keim K.L., Sigg E.B. Plasma corticosterone and brain catecholamines in stress: Effect of psychotropic drugs. Pharmacology, Biochemistry, and Behavior 1977, 6(1):79-85.
117. Keller C.M., Cornett E.M., Guerin G.F., Goeders N.E. Combinations of oxazepam and metyrapone attenuate cocaine and methamphetamine cue reactivity. Drug and Alcohol Dependence 2013, 133(2):405-412.
118. Kelley A.M., Athy J.R., Cho T.H., Erickson B., King M., Cruz P. Risk propensity and health risk behaviors in U.S. army soldiers with and without psychological disturbances across the deployment cycle. Journal of Psychiatric Research 2012, 46(5):582-589.
119. Khantzian E.J. The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. The American Journal of Psychiatry 1985, 142(11):1259-1264.
120. Kilbey M.M., Breslau N., Andreski P. Cocaine use and dependence in young adults: Associated psychiatric disorders and personality traits. Drug and Alcohol Dependence 1992, 29(3):283-290.
121. Kilgus M.D., Pumariega A.J. Experimental manipulation of cocaine craving by videotaped environmental cues. Southern Medical Journal 1994, 87(11):1138-1140.
122. Kilts C.D., Schweitzer J.B., Quinn C.K., Gross R.E., Faber T.L., Muhammad F., et al. Neural activity related to drug craving in cocaine addiction. Archives of General Psychiatry 2001, 58(4):334-341.
123. Kleber H.D., Gawin F.H. Cocaine abuse: A review of current and experimental treatments. NIDA Research Monograph 1984, 50:111-129.
124. Koob G.F. A role for brain stress systems in addiction. Neuron 2008, 59(1):11-34.
125. Koob G.F., Buck C.L., Cohen A., Edwards S., Park P.E., Schlosburg J.E., et al. Addiction as a stress surfeit disorder. Neuropharmacology 2014, 76(Part B):370-382.
126. Kostowski W. Recent advances in the GABA-A-benzodiazepine receptor pharmacology. Polish Journal of Pharmacology 1995, 47(3):237-246.
127. Kreek M.J., Ragunath J., Plevy S., Hamer D., Schneider B., Hartman N. ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 1984, 5(1-3):277-278.
128. Lambert J.J., Belelli D., Hill-Venning C., Callachan H., Peters J.A. Neurosteroid modulation of native and recombinant GABAA receptors. Cellular and Molecular Neurobiology 1996, 16(2):155-174.
129. Lambert J.J., Belelli D., Peden D.R., Vardy A.W., Peters J.A. Neurosteroid modulation of GABAA receptors. Progress in Neurobiology 2003, 71(1):67-80.
130. Lange R.A., Hillis L.D. Cardiovascular complications of cocaine use. The New England Journal of Medicine 2001, 345(5):351-358.
131. Lee B., Tiefenbacher S., Platt D.M., Spealman R.D. Role of the hypothalamic-pituitary-adrenal axis in reinstatement of cocaine-seeking behavior in squirrel monkeys. Psychopharmacology 2003, 168(1-2):177-183.
132. Lelas S., Rowlett J.K., Spealman R.D. Triazolam discrimination in squirrel monkeys distinguishes high-efficacy agonists from other benzodiazepines and non-benzodiazepine drugs. Psychopharmacology 2001, 154(1):96-104.
133. Lemaire V., Deminiere J.M., Mormede P. Chronic social stress conditions differentially modify vulnerability to amphetamine self-administration. Brain Research 1994, 649(1-2):348-352.
134. Levy A.D., Li Q.A., Kerr J.E., Rittenhouse P.A., Milonas G., Cabrera T.M., et al. Cocaine-induced elevation of plasma adrenocorticotropin hormone and corticosterone is mediated by serotonergic neurons. The Journal of Pharmacology and Experimental Therapeutics 1991, 259(2):495-500.
135. Lilja J., Larsson S., Skinhoj K.T., Hamilton D. Evaluation of programs for the treatment of benzodiazepine dependency. Substance Use & Misuse 2001, 36(9-10):1213-1231.
136. Lipton J.W., Olsen R.W., Ellison G.D. Length of continuous cocaine exposure determines the persistence of muscarinic and benzodiazepine receptor alterations. Brain Research 1995, 676(2):378-385.
137. London E.D., Ernst M., Grant S., Bonson K., Weinstein A. Orbitofrontal cortex and human drug abuse: Functional imaging. Cerebral Cortex 2000, 10(3):334-342.
138. Longone P., Rupprecht R., Manieri G.A., Bernardi G., Romeo E., Pasini A. The complex roles of neurosteroids in depression and anxiety disorders. Neurochemistry International 2008, 52(4-5):596-601.
139. Loose D.S., Stover E.P., Feldman D. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. The Journal of Clinical Investigation 1983, 72(1):404-408.
140. Lovallo W.R. The hypothalamic-pituitary-adrenocortical axis in addiction. International Journal of Psychophysiology 2006, 59(3):193-194.
141. Luddens H., Korpi E.R. Biological function of GABAA/benzodiazepine receptor heterogeneity. Journal of Psychiatric Research 1995, 29(2):77-94.
142. Maas L.C., Lukas S.E., Kaufman M.J., Weiss R.D., Daniels S.L., Rogers V.W., et al. Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving. The American Journal of Psychiatry 1998, 155(1):124-126.
143. Maayan R., Lotan S., Doron R., Shabat-Simon M., Gispan-Herman I., Weizman A., et al. Dehydroepiandrosterone (DHEA) attenuates cocaine-seeking behavior in the self-administration model in rats. European Neuropsychopharmacology 2006, 16(5):329-339.
144. MacKenzie S.M., Clark C.J., Fraser R., Gomez-Sanchez C.E., Connell J.M., Davies E. Expression of 11beta-hydroxylase and aldosterone synthase genes in the rat brain. Journal of Molecular Endocrinology 2000, 24(3):321-328.
145. MacKenzie S.M., Clark C.J., Ingram M.C., Lai M., Seckl J., Gomez-Sanchez C.E., et al. Corticosteroid production by fetal rat hippocampal neurons. Endocrine Research 2000, 26(4):531-535.
146. Maksay G., Tegyey Z., Simonyi M. Central benzodiazepine receptors: In vitro efficacies and potencies of 3-substituted 1,4-benzodiazepine stereoisomers. Molecular Pharmacology 1991, 39(6):725-732.
147. Mantsch J.R., Goeders N.E. Generalization of a restraint-induced discriminative stimulus to cocaine in rats. Psychopharmacology 1998, 135(4):423-426.
148. Mantsch J.R., Goeders N.E. Ketoconazole blocks the stress-induced reinstatement of cocaine-seeking behavior in rats: Relationship to the discriminative stimulus effects of cocaine. Psychopharmacology 1999, 142(4):399-407.
149. Mantsch J.R., Goeders N.E. Ketoconazole does not block cocaine discrimination or the cocaine-induced reinstatement of cocaine-seeking behavior. Pharmacology, Biochemistry, and Behavior 1999, 64(1):65-73.
150. Mantsch J.R., Saphier D., Goeders N.E. Corticosterone facilitates the acquisition of cocaine self-administration in rats: Opposite effects of the type II glucocorticoid receptor agonist dexamethasone. The Journal of Pharmacology and Experimental Therapeutics 1998, 287(1):72-80.
151. Martin I.L. The benzodiazepines and their receptors: 25 years of progress. Neuropharmacology 1987, 26(7B):957-970.
152. McCarthy J.R., Heinrichs S.C., Grigoriadis D.E. Recent advances with the CRF1 receptor: Design of small molecule inhibitors, receptor subtypes and clinical indications. Current Pharmaceutical Design 1999, 5(5):289-315.
153. McEwen B.S., Weiss J.M., Schwartz L.S. Selective retention of corticosterone by limbic structures in rat brain. Nature 1968, 220(5170):911-912.
154. Meador-Woodruff J.H., Greden J.F. Effects of psychotropic medications on hypothalamic-pituitary-adrenal regulation. Endocrinology and Metabolism Clinics of North America 1988, 17(1):225-234.
155. Meil W.M., See R.E. Conditioned cued recovery of responding following prolonged withdrawal from self-administered cocaine in rats: An animal model of relapse. Behavioural Pharmacology 1996, 7(8):754-763.
156. Mello N.K., Negus S.S., Rice K.C., Mendelson J.H. Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. Pharmacology, Biochemistry, and Behavior 2006, 85(4):744-751.
157. Mendelson J.H., Mello N.K., Teoh S.K., Ellingboe J., Cochin J. Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. The Journal of Clinical Endocrinology and Metabolism 1989, 69(6):1256-1260.
158. Mendelson J.H., Sholar M., Mello N.K., Teoh S.K., Sholar J.W. Cocaine tolerance: Behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacology 1998, 18(4):263-271.
159. Mendelson J.H., Teoh S.K., Mello N.K., Ellingboe J., Rhoades E. Acute effects of cocaine on plasma adrenocorticotropic hormone, luteinizing hormone and prolactin levels in cocaine-dependent men. The Journal of Pharmacology and Experimental Therapeutics 1992, 263(2):505-509.
160. Miczek K.A., Mutschler N.H. Activational effects of social stress on IV cocaine self-administration in rats. Psychopharmacology 1996, 128(3):256-264.
161. Miller L.G., Greenblatt D.J., Barnhill J.G., Thompson M.L., Shaderh R.I. Modulation of benzodiazepine receptor binding in mouse brain by adrenalectomy and steroid replacement. Brain Research 1988, 446(2):314-320.
162. Moffett M.C., Goeders N.E. CP-154,526, a CRF type-1 receptor antagonist, attenuates the cue-and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats. Psychopharmacology 2007, 190(2):171-180.
163. Moldow R.L., Fischman A.J. Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone. Peptides 1987, 8(5):819-822.
164. Monder C., Lakshmi V., Miroff Y. Kinetic studies on rat liver 11 beta-hydroxysteroid dehydrogenase. Biochimica et Biophysica Acta 1991, 1115(1):23-29.
165. Mukai Y., Higashi T., Nagura Y., Shimada K. Studies on neurosteroids XXV. Influence of a 5alpha-reductase inhibitor, finasteride, on rat brain neurosteroid levels and metabolism. Biological & Pharmaceutical Bulletin 2008, 31(9):1646-1650.
166. Mukhin A.G., Papadopoulos V., Costa E., Krueger K.E. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. Proceedings of the National Academy of Sciences of the United States of America 1989, 86(24):9813-9816.
167. Mumford G.K., Evans S.M., Fleishaker J.C., Griffiths R.R. Alprazolam absorption kinetics affects abuse liability. Clinical Pharmacology and Therapeutics 1995, 57(3):356-365.
168. Murphy B.E., Ghadirian A.M., Dhar V. Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy. Canadian Journal of Psychiatry 1998, 43(3):279-286.
169. Mutschler N.H., Miczek K.A. Withdrawal from a self-administered or non-contingent cocaine binge: Differences in ultrasonic distress vocalizations in rats. Psychopharmacology 1998, 136(4):402-408.
170. Mutschler N.H., Miczek K.A. Withdrawal from i.v. cocaine "binges" in rats: Ultrasonic distress calls and startle. Psychopharmacology 1998, 135(2):161-168.
171. Nader M.A., Czoty P.W., Nader S.H., Morgan D. Nonhuman primate models of social behavior and cocaine abuse. Psychopharmacology 2012, 224(1):57-67. 10.1007/s00213-012-2843-5.
172. Negus S.S., Mello N.K., Fivel P.A. Effects of GABA agonists and GABA-A receptor modulators on cocaine discrimination in rhesus monkeys. Psychopharmacology 2000, 152(4):398-407.
173. Nemeroff C.B. The role of corticotropin-releasing factor in the pathogenesis of major depression. Pharmacopsychiatry 1988, 21(2):76-82. 10.1055/s-2007-1014652.
174. Nothdurfter C., Rammes G., Baghai T.C., Schule C., Schumacher M., Papadopoulos V., et al. Translocator protein (18kDa) as a target for novel anxiolytics with a favourable side-effect profile. Journal of Neuroendocrinology 2012, 24(1):82-92.
175. O'Brien C.P. Benzodiazepine use, abuse, and dependence. The Journal of Clinical Psychiatry 2005, 66(Suppl. 2):28-33.
176. Ongur D., Price J.L. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cerebral Cortex 2000, 10(3):206-219.
177. Oreland L. The benzodiazepines: A pharmacological overview. Acta Anaesthesiologica Scandinavica. Supplementum 1988, 88:13-16.
178. Palamarchouk V., Smagin G., Goeders N.E. Self-administered and passive cocaine infusions produce different effects on corticosterone concentrations in the medial prefrontal cortex (MPC) of rats. Pharmacology, Biochemistry, and Behavior 2009, 94(1):163-168.
179. Paliwal P., Hyman S.M., Sinha R. Craving predicts time to cocaine relapse: Further validation of the Now and Brief versions of the cocaine craving questionnaire. Drug and Alcohol Dependence 2008, 93(3):252-259.
180. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapere J.J., Lindemann P., et al. Translocator protein (18kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends in Pharmacological Sciences 2006, 27(8):402-409.
181. Papadopoulos V., Berkovich A., Krueger K.E. The role of diazepam binding inhibitor and its processing products at mitochondrial benzodiazepine receptors: Regulation of steroid biosynthesis. Neuropharmacology 1991, 30(12B):1417-1423.
182. Paul S.M., Purdy R.H. Neuroactive steroids. The FASEB Journal 1992, 6(6):2311-2322.
183. Pellow S., Chopin P., File S.E., Briley M. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods 1985, 14(3):149-167.
184. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat. Pharmacology, Biochemistry, and Behavior 1986, 24(3):525-529.
185. Peltier R.L., Guerin G.F., Dorairaj N., Goeders N.E. Effects of saline substitution on responding and plasma corticosterone in rats trained to self-administer different doses of cocaine. The Journal of Pharmacology and Experimental Therapeutics 2001, 299(1):114-120.
186. Piazza P.V., Deminiere J.M., le Moal M., Simon H. Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Research 1990, 514(1):22-26.
187. Pinna G., Rasmusson A.M. Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder. Journal of Neuroendocrinology 2012, 24(1):102-116.
188. Pitts A.F., Samuelson S.D., Meller W.H., Bissette G., Nemeroff C.B., Kathol R.G. Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. Biological Psychiatry 1995, 38(5):330-335.
189. Potts L.A., Garwood C.L. Varenicline: The newest agent for smoking cessation. American Journal of Health-System Pharmacy 2007, 64(13):1381-1384.
190. Purdy R.H., Moore P.H., Morrow A.L., Paul S.M. Neurosteroids and GABAA receptor function. Advances in Biochemical Psychopharmacology 1992, 47:87-92.
191. Ramsey N.F., Van Ree J.M. Emotional but not physical stress enhances intravenous cocaine self-administration in drug-naive rats. Brain Research 1993, 608(2):216-222.
192. Raven P.W., Checkley S.A., Taylor N.F. Extra-adrenal effects of metyrapone include inhibition of the 11-oxoreductase activity of 11 beta-hydroxysteroid dehydrogenase: A model for 11-HSD I deficiency. Clinical Endocrinology 1995, 43(5):637-644.
193. Raven P.W., O'Dwyer A.M., Taylor N.F., Checkley S.A. The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinology 1996, 21(3):277-286.
194. Rivier C., Lee S. Stimulatory effect of cocaine on ACTH secretion: Role of the hypothalamus. Molecular and Cellular Neurosciences 1994, 5(2):189-195.
195. Rivier C., Vale W. Cocaine stimulates adrenocorticotropin (ACTH) secretion through a corticotropin-releasing factor (CRF)-mediated mechanism. Brain Research 1987, 422(2):403-406.
196. Robbins S.J., Ehrman R.N., Childress A.R., O'Brien C.P. Using cue reactivity to screen medications for cocaine abuse: A test of amantadine hydrochloride. Addictive Behaviors 1992, 17(5):491-499.
197. Robel P., Baulieu E.E. Neurosteroids: Biosynthesis and function. Critical Reviews in Neurobiology 1995, 9(4):383-394.
198. Rogerio R., Takahashi R.N. Anxiogenic properties of cocaine in the rat evaluated with the elevated plus-maze. Pharmacology, Biochemistry, and Behavior 1992, 43(2):631-633.
199. Romeo E., Cavallaro S., Korneyev A., Kozikowski A.P., Ma D., Polo A., et al. Stimulation of brain steroidogenesis by 2-aryl-indole-3-acetamide derivatives acting at the mitochondrial diazepam-binding inhibitor receptor complex. The Journal of Pharmacology and Experimental Therapeutics 1993, 267(1):462-471.
200. Rounsaville B.J. Treatment of cocaine dependence and depression. Biological Psychiatry 2004, 56(10):803-809.
201. Rounsaville B.J., Anton S.F., Carroll K., Budde D., Prusoff B.A., Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Archives of General Psychiatry 1991, 48(1):43-51.
202. Rupprecht R., Papadopoulos V., Rammes G., Baghai T.C., Fan J., Akula N., et al. Translocator protein (18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature Reviews. Drug Discovery 2010, 9(12):971-988.
203. Rupprecht R., Rammes G., Eser D., Baghai T.C., Schule C., Nothdurfter C., et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009, 325(5939):490-493.
204. Rupprecht R., Strohle A., Hermann B., di Michele F., Spalletta G., Pasini A., et al. Neuroactive steroid concentrations following metyrapone administration in depressed patients and healthy volunteers. Biological Psychiatry 1998, 44(9):912-914.
205. Rush C.R., Stoops W.W., Wagner F.P., Hays L.R., Glaser P.E. Alprazolam attenuates the behavioral effects of d-amphetamine in humans. Journal of Clinical Psychopharmacology 2004, 24(4):410-420.
206. Saal D., Dong Y., Bonci A., Malenka R.C. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 2003, 37(4):577-582.
207. Sampath-Kumar R., Yu M., Khalil M.W., Yang K. Metyrapone is a competitive inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 reductase. The Journal of Steroid Biochemistry and Molecular Biology 1997, 62(2-3):195-199.
208. Sanchez M.M., Young L.J., Plotsky P.M., Insel T.R. Distribution of corticosteroid receptors in the rhesus brain: Relative absence of glucocorticoid receptors in the hippocampal formation. The Journal of Neuroscience 2000, 20(12):4657-4668.
209. Sanger D.J. GABA and the behavioral effects of anxiolytic drugs. Life Sciences 1985, 36(16):1503-1513.
210. Saphier D., Welch J.E., Farrar G.E., Goeders N.E. Effects of intracerebroventricular and intrahypothalamic cocaine administration on adrenocortical secretion. Neuroendocrinology 1993, 57(1):54-62.
211. Sarnyai Z., Biro E., Gardi J., Vecsernyes M., Julesz J., Telegdy G. Alterations of corticotropin-releasing factor-like immunoreactivity in different brain regions after acute cocaine administration in rats. Brain Research 1993, 616(1-2):315-319.
212. Sarnyai Z., Biro E., Gardi J., Vecsernyes M., Julesz J., Telegdy G. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Research 1995, 675(1-2):89-97.
213. Sarnyai Z., Biro E., Penke B., Telegdy G. The cocaine-induced elevation of plasma corticosterone is mediated by endogenous corticotropin-releasing factor (CRF) in rats. Brain Research 1992, 589(1):154-156.
214. Sarnyai Z., Mello N.K., Mendelson J.H., Eros-Sarnyai M., Mercer G. Effects of cocaine on pulsatile activity of hypothalamic-pituitary-adrenal axis in male rhesus monkeys: Neuroendocrine and behavioral correlates. The Journal of Pharmacology and Experimental Therapeutics 1996, 277(1):225-234.
215. Schenk S., Lacelle G., Gorman K., Amit Z. Cocaine self-administration in rats influenced by environmental conditions: Implications for the etiology of drug abuse. Neuroscience Letters 1987, 81(1-2):227-231.
216. Schenk S., Partridge B. Sensitization and tolerance in psychostimulant self-administration. Pharmacology, Biochemistry, and Behavior 1997, 57(3):543-550.
217. Schenk S., Snow S. Sensitization to cocaine's motor activating properties produced by electrical kindling of the medial prefrontal cortex but not of the hippocampus. Brain Research 1994, 659(1-2):17-22.
218. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., et al. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(19):10477-10482.
219. See R.E. Neural substrates of cocaine-cue associations that trigger relapse. European Journal of Pharmacology 2005, 526(1-3):140-146.
220. Sellers E.M., Ciraulo D.A., DuPont R.L., Griffiths R.R., Kosten T.R., Romach M.K., et al. Alprazolam and benzodiazepine dependence. The Journal of Clinical Psychiatry 1993, 54(Suppl.):64-75. Discussion 67-76.
221. Selye H. Stress and distress. Comprehensive Therapy 1975, 1(8):9-13.
222. Shaham Y., Erb S., Leung S., Buczek Y., Stewart J. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology 1998, 137(2):184-190.
223. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology 2003, 168(1-2):3-20.
224. Shearman G.T., Lal H. Generalization and antagonism studies with convulsant, GABAergic and anticonvulsant drugs in rats trained to discriminate pentylenetetrazol from saline. Neuropharmacology 1980, 19(5):473-479.
225. Shearman G.T., Lal H. Discriminative stimulus properties of cocaine related to an anxiogenic action. Progress in Neuro-Psychopharmacology 1981, 5(1):57-63.
226. Shiffman S., Read L., Jarvik M.E. Smoking relapse situations: A preliminary typology. The International Journal of the Addictions 1985, 20(2):311-318.
227. Sinha R., Catapano D., O'Malley S. Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology 1999, 142(4):343-351.
228. Sinha R., Garcia M., Paliwal P., Kreek M.J., Rounsaville B.J. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Archives of General Psychiatry 2006, 63(3):324-331.
229. Sinha R., Li C.S. Imaging stress- and cue-induced drug and alcohol craving: Association with relapse and clinical implications. Drug and Alcohol Review 2007, 26(1):25-31.
230. Sinha R., Talih M., Malison R., Cooney N., Anderson G.M., Kreek M.J. Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology 2003, 170(1):62-72.
231. Smagin G.N., Goeders N.E. Effects of acute and chronic ketoconazole administration on hypothalamo-pituitary-adrenal axis activity and brain corticotropin-releasing hormone. Psychoneuroendocrinology 2004, 29(10):1223-1228.
232. Soderpalm B. Pharmacology of the benzodiazepines; with special emphasis on alprazolam. Acta Psychiatrica Scandinavica. Supplementum 1987, 335:39-46.
233. Sonino N. The use of ketoconazole as an inhibitor of steroid production. The New England Journal of Medicine 1987, 317(13):812-818.
234. Sorg B.A., Chen S.Y., Kalivas P.W. Time course of tyrosine hydroxylase expression after behavioral sensitization to cocaine. The Journal of Pharmacology and Experimental Therapeutics 1993, 266(1):424-430.
235. Spero L. Modulation of specific [3H]phenytoin binding by benzodiazepines. Neurochemical Research 1985, 10(6):755-765.
236. Spivak B., Maayan R., Kotler M., Mester R., Gil-Ad I., Shtaif B., et al. Elevated circulatory level of GABA(A)-Antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psychological Medicine 2000, 30(5):1227-1231.
237. Stefanski R., Ziolkowska B., Kusmider M., Mierzejewski P., Wyszogrodzka E., Kolomanska P., et al. Active versus passive cocaine administration: Differences in the neuroadaptive changes in the brain dopaminergic system. Brain Research 2007, 1157:1-10.
238. Steiner J.F. Finasteride: A 5 alpha-reductase inhibitor. Clinical Pharmacy 1993, 12(1):15-23.
239. Stewart J. Pathways to relapse: The neurobiology of drug- and stress-induced relapse to drug-taking. Journal of Psychiatry & Neuroscience 2000, 25(2):125-136.
240. Stratakis C.A., Chrousos G.P. Neuroendocrinology and pathophysiology of the stress system. Annals of the New York Academy of Sciences 1995, 771:1-18.
241. Stromstedt M., Waterman M.R. Messenger RNAs encoding steroidogenic enzymes are expressed in rodent brain. Brain Research. Molecular Brain Research 1995, 34(1):75-88.
242. Sudduth S.L., Koronkowski M.J. Finasteride: The first 5 alpha-reductase inhibitor. Pharmacotherapy 1993, 13(4):309-325. Discussion 309-325.
243. Suto N., Ecke L.E., You Z.B., Wise R.A. Extracellular fluctuations of dopamine and glutamate in the nucleus accumbens core and shell associated with lever-pressing during cocaine self-administration, extinction, and yoked cocaine administration. Psychopharmacology 2010, 211(3):267-275.
244. Tarr J.E., Macklin M. Cocaine. Pediatric Clinics of North America 1987, 34(2):319-331.
245. Temple T.E., Liddle G.W. Inhibitors of adrenal steroid biosynthesis. Annual Review of Pharmacology 1970, 10:199-218.
246. Teoh S.K., Sarnyai Z., Mendelson J.H., Mello N.K., Springer S.A., Sholar J.W., et al. Cocaine effects on pulsatile secretion of ACTH in men. The Journal of Pharmacology and Experimental Therapeutics 1994, 270(3):1134-1138.
247. Thakore J.H., Dinan T.G. Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression. Biological Psychiatry 1995, 37(6):364-368.
248. Thomson I., Fraser R., Kenyon C.J. Regulation of adrenocortical steroidogenesis by benzodiazepines. The Journal of Steroid Biochemistry and Molecular Biology 1995, 53(1-6):75-79.
249. Tidey J.W., Miczek K.A. Acquisition of cocaine self-administration after social stress: Role of accumbens dopamine. Psychopharmacology 1997, 130(3):203-212.
250. Tokuda K., O'Dell K.A., Izumi Y., Zorumski C.F. Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis. The Journal of Neuroscience 2010, 30(50):16788-16795.
251. Torpy D.J., Grice J.E., Hockings G.I., Walters M.M., Crosbie G.V., Jackson R.V. Alprazolam blocks the naloxone-stimulated hypothalamo-pituitary-adrenal axis in man. The Journal of Clinical Endocrinology and Metabolism 1993, 76(2):388-391.
252. Trapani A., Palazzo C., de Candia M., Lasorsa F.M., Trapani G. Targeting of the translocator protein 18kDa (TSPO): A valuable approach for nuclear and optical imaging of activated microglia. Bioconjugate Chemistry 2013, 24:1415-1428.
253. Twining R.C., Bolan M., Grigson P.S. Yoked delivery of cocaine is aversive and protects against the motivation for drug in rats. Behavioral Neuroscience 2009, 123(4):913-925.
254. Ugale R.R., Mittal N., Hirani K., Chopde C.T. Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazole-induced seizures in mice. Brain Research 2004, 1023(1):102-111.
255. Ugale R.R., Sharma A.N., Kokare D.M., Hirani K., Subhedar N.K., Chopde C.T. Neurosteroid allopregnanolone mediates anxiolytic effect of etifoxine in rats. Brain Research 2007, 1184:193-201.
256. Usami N., Yamamoto T., Shintani S., Ishikura S., Higaki Y., Katagiri Y., et al. Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biological & Pharmaceutical Bulletin 2002, 25(4):441-445.
257. Van Cauteren H., Lampo A., Vandenberghe J., Vanparys P., Coussement W., De Coster R., et al. Toxicological profile and safety evaluation of antifungal azole derivatives. Mycoses 1989, 32(Suppl. 1):60-66.
258. Van Cauteren H., Lampo A., Vandenberghe J., Vanparys P., Coussement W., De Coster R., et al. Safety aspects of oral antifungal agents. British Journal of Clinical Practice. Supplement 1990, 71:47-49.
259. Van Vugt D.A., Piercy J., Farley A.E., Reid R.L., Rivest S. Luteinizing hormone secretion and corticotropin-releasing factor gene expression in the paraventricular nucleus of rhesus monkeys following cortisol synthesis inhibition. Endocrinology 1997, 138(6):2249-2258.
260. Venkatakrishnan K., Rader M., Ramanathan R.K., Ramalingam S., Chen E., Riordan W., et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clinical Therapeutics 2009, 31(Pt. 2):2444-2458.
261. Vescovi P.P., Coiro V., Volpi R., Giannini A., Passeri M. Hyperthermia in sauna is unable to increase the plasma levels of ACTH/cortisol, beta-endorphin and prolactin in cocaine addicts. Journal of Endocrinological Investigation 1992, 15(9):671-675.
262. Vescovi P.P., Coiro V., Volpi R., Passeri M. Diurnal variations in plasma ACTH, cortisol and beta-endorphin levels in cocaine addicts. Hormone Research 1992, 37(6):221-224.
263. Wang J.K., Taniguchi T., Spector S. Structural requirements for the binding of benzodiazepines to their peripheral-type sites. Molecular Pharmacology 1984, 25(3):349-351.
264. Wang G.J., Volkow N.D., Fowler J.S., Cervany P., Hitzemann R.J., Pappas N.R., et al. Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sciences 1999, 64(9):775-784.
265. Washton A.M., Tatarsky A. Adverse effects of cocaine abuse. NIDA Research Monograph 1984, 49:247-254.
266. Wehling M. Specific, nongenomic actions of steroid hormones. Annual Review of Physiology 1997, 59:365-393.
267. Weiss F., Maldonado-Vlaar C.S., Parsons L.H., Kerr T.M., Smith D.L., Ben-Shahar O. Control of cocaine-seeking behavior by drug-associated stimuli in rats: Effects on recovery of extinguished operant-responding and extracellular dopamine levels in amygdala and nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(8):4321-4326.
268. Wesson D.R., Smith D.E. Cocaine: Treatment perspectives. NIDA Research Monograph 1985, 61:193-203.
269. Wilkins J.N. Brain, lung, and cardiovascular interactions with cocaine and cocaine-induced catecholamine effects. Journal of Addictive Diseases 1992, 11(4):9-19.
270. Wolf B., Griffiths R.R. Physical dependence on benzodiazepines: Differences within the class. Drug and Alcohol Dependence 1991, 29(2):153-156.
271. Wolkowitz O.M., Reus V.I., Manfredi F., Ingbar J., Brizendine L., Weingartner H. Ketoconazole administration in hypercortisolemic depression. The American Journal of Psychiatry 1993, 150(5):810-812.
272. Wood D.M., Lal H. Anxiogenic properties of cocaine withdrawal. Life Sciences 1987, 41(11):1431-1436.
273. Yang X.M., Gorman A.L., Dunn A.J., Goeders N.E. Anxiogenic effects of acute and chronic cocaine administration: Neurochemical and behavioral studies. Pharmacology, Biochemistry, and Behavior 1992, 41(3):643-650.
274. Ye P., Kenyon C.J., Mackenzie S.M., Nichol K., Seckl J.R., Fraser R., et al. Effects of ACTH, dexamethasone, and adrenalectomy on 11beta-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) gene expression in the rat central nervous system. The Journal of Endocrinology 2008, 196(2):305-311.
275. Zeigler S., Lipton J., Toga A., Ellison G. Continuous cocaine administration produces persisting changes in brain neurochemistry and behavior. Brain Research 1991, 552(1):27-35.
276. Zierler-Brown S.L., Kyle J.A. Oral varenicline for smoking cessation. The Annals of Pharmacotherapy 2007, 41(1):95-99.
277. Zorumski C.F., Paul S.M., Izumi Y., Covey D.F., Mennerick S. Neurosteroids, stress and depression: Potential therapeutic opportunities. Neuroscience and Biobehavioral Reviews 2013, 37(1):109-122.